Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
4TEEN4 Pharmaceuticals GmbH has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 4 distinct examiners and 4 distinct art units, indicating that the portfolio reaches multiple examination assignments rather than one concentrated docket.
KARUNASENA, ENUSHA is the busiest examiner, with 1 pending matter. The profile provides no basis for attributing the portfolio’s prosecution posture to a single examiner. A practical review should therefore track each application separately while checking for reusable arguments, consistent terminology, and disclosure support across the biotechnology matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KARUNASENA, ENUSHA | 1 | 25.0% | +100.0% |
| WEN, SHARON X | 1 | 56.8% | +32.6% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18338805 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | KARUNASENA, ENUSHA | — |
| 16095563 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | CHEONG, CHEOM-GIL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17984611 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | WEN, SHARON X | 45d overdue |
| 18338805 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | KARUNASENA, ENUSHA | — |
| 17802799 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | AEDER, SEAN E | — |
| 16095563 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | CHEONG, CHEOM-GIL | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1641 | 1 |
| 1642 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18338805 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | KARUNASENA, ENUSHA | 1653 | §112DP | Non-Final OA | — | Pending | Jun 21, 2023 |
| 17984611 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | WEN, SHARON X | 1641 | §103§112DP | Final Rejection | 45d overdue | Pending | Nov 10, 2022 |
| 17802799 | DPP3 FOR THERAPY GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK | AEDER, SEAN E | 1642 | §103Other | Final Rejection | — | Pending | Aug 26, 2022 |
| 16095563 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | CHEONG, CHEOM-GIL | 1645 | §101 | Non-Final OA | — | Pending | Oct 22, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial4TEEN4 Pharmaceuticals GmbH has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Enusha Karunasena has the most, with 1 of 4TEEN4 Pharmaceuticals GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
